OBJECTIVE: To evaluate the effects of 20 weeks of resistance and concurrent training on psychotic and depressive symptoms, quality of life outcomes, and serum IGF-1, IGFBP-3, and brain-derived neurotrophic factor (BDNF) concentrations in patients with schizophrenia. METHODS: In this blind, randomized controlled clinical trial, 34 patients with schizophrenia were assigned to one of three groups: control (CTRL, n=13), resistance exercise (RESEX, n=12), or concurrent exercise (CONCEX, n=9). Symptoms, quality of life, strength, and other variables were assessed. RESULTS: A significant time-by-group interaction was found for the RESEX and CONCEX groups on the Positive and Negative Syndrome Scale (PANSS) total score for disease symptoms (p = 0.007), positive symptoms (p = 0.003), and on the arm extension one-repetition maximum (1RM) test (p = 0.016). In addition, significant improvements on negative symptoms (p = 0.027), on the role-physical domain of the Short Form-36 Health Survey (p = 0.019), and on the chest press 1RM test (p = 0.040) were observed in the RESEX group. No changes were observed for the other variables investigated. CONCLUSIONS: In this sample of patients with schizophrenia, 20 weeks of resistance orconcurrent exercise program improved disease symptoms, strength, and quality of life. ClinicalTrials.gov: NCT01674543.
RCT Entities:
OBJECTIVE: To evaluate the effects of 20 weeks of resistance and concurrent training on psychotic and depressive symptoms, quality of life outcomes, and serum IGF-1, IGFBP-3, and brain-derived neurotrophic factor (BDNF) concentrations in patients with schizophrenia. METHODS: In this blind, randomized controlled clinical trial, 34 patients with schizophrenia were assigned to one of three groups: control (CTRL, n=13), resistance exercise (RESEX, n=12), or concurrent exercise (CONCEX, n=9). Symptoms, quality of life, strength, and other variables were assessed. RESULTS: A significant time-by-group interaction was found for the RESEX and CONCEX groups on the Positive and Negative Syndrome Scale (PANSS) total score for disease symptoms (p = 0.007), positive symptoms (p = 0.003), and on the arm extension one-repetition maximum (1RM) test (p = 0.016). In addition, significant improvements on negative symptoms (p = 0.027), on the role-physical domain of the Short Form-36 Health Survey (p = 0.019), and on the chest press 1RM test (p = 0.040) were observed in the RESEX group. No changes were observed for the other variables investigated. CONCLUSIONS: In this sample of patients with schizophrenia, 20 weeks of resistance or concurrent exercise program improved disease symptoms, strength, and quality of life. ClinicalTrials.gov: NCT01674543.
Authors: Brian R Barnett; Jacqueline M Anderson; Maribel Torres-Velázquez; Sue Y Yi; Paul A Rowley; John-Paul J Yu Journal: Magn Reson Imaging Date: 2019-05-16 Impact factor: 2.546
Authors: Vijay A Mittal; Teresa Vargas; K Juston Osborne; Derek Dean; Tina Gupta; Ivanka Ristanovic; Christine I Hooker; Stewart A Shankman Journal: Curr Treat Options Psychiatry Date: 2017-04-18
Authors: Mehala Subramaniapillai; Kelly Arbour-Nicitopoulos; Markus Duncan; Roger S McIntyre; Rodrigo B Mansur; Gary Remington; Guy Faulkner Journal: BMC Res Notes Date: 2016-07-12
Authors: Joseph Firth; Brendon Stubbs; Simon Rosenbaum; Davy Vancampfort; Berend Malchow; Felipe Schuch; Rebecca Elliott; Keith H Nuechterlein; Alison R Yung Journal: Schizophr Bull Date: 2017-05-01 Impact factor: 9.306
Authors: Hélio José Coelho-Júnior; Ivan de Oliveira Gonçalves; Ricardo Aurélio Carvalho Sampaio; Priscila Yukari Sewo Sampaio; Eduardo Lusa Cadore; Riccardo Calvani; Anna Picca; Mikel Izquierdo; Emanuele Marzetti; Marco Carlos Uchida Journal: Int J Environ Res Public Health Date: 2020-05-14 Impact factor: 3.390